TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
ASCO 2023 Annual Meeting Poster Presentation Potential predictive biomarker for clinical response |
Press Release2023, May 30 08:00 a.m. TME Pharma announces convocation of the 2023 annual general meeting of shareholders 2023, May 26 08:00 a.m. TME Pharma announces publication of ASCO 2023 abstract disclosing new biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma 2023, May 25 06:00 p.m. TME Pharma provides positive clinical update and 14-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma |
EventsASCO Annual Meeting 2023
Aram Mangasarian, Avital Barak BIO International Convention
Aram Mangasarian, Dirk Eulberg, Ewelina Staniuk |